Development of anti-CD30 radioimmunoconstructs (RICs) for treatment of Hodgkin's lymphoma: Studies with cell lines and animal studies

NuklearMedizin

Volumn 49, Issue 3, 2010, Pages 97-105

  Dietlein, M ^a   Borner S M ^a   Fischer, T ^a   Hansen, H ^a   Schnell, R ^a   Zimmermanns, B ^a   Tawadros, S ^a   Engert, A ^a   Staak, O ^a   Von Strandmann, E Pogge ^a   Kobe, C ^a   Schicha, H ^a   Schomacker K ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Anti CD30; Hodgkin's lymphoma; Ki 4; Radioimmunoconjugates; Radioimmunotherapy

Indexed keywords

CD30 ANTIGEN; MONOCLONAL ANTIBODY 5F11 BENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; MONOCLONAL ANTIBODY 5F11 I 131; MONOCLONAL ANTIBODY KI 4 BENZYL 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; MONOCLONAL ANTIBODY KI 4 I 131; RADIOIMMUNOCONJUGATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CONTROLLED STUDY; DISSOCIATION CONSTANT; HODGKIN DISEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; SCATCHARD PLOT; SCID MOUSE; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CELL DIVISION; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MICE; RADIOTHERAPY; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 77952822600     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0258     Document Type: Article

References (47)

1. Adams GP, Schier R, McCall AM et al.. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-4755. (Pubitemid 32691886)
2. Borchmann P, Schnell R, Engert A. Immunotherapy of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; 66: 159-165.
3. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3-13. (Pubitemid 351347529)
4. Dahle J, Krogh C, Melhus KB et al. A one-step method for determining the maximum number of bound antibodies, and the affinity and association rate constants for antibody binding. Nucl Med Commun 2007; 28: 742-747. (Pubitemid 47220409)
5. 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008; 35: 1507-1515.
6. Diehl V, Kirchner HH, Schaadt M et al. Hodgkin's disease: establishment and characterization of four in vitro cell lines. J Cancer Res Clin Oncol 1981; 101: 111-124.
7. Diehl V, Kirchner HH, Burrichter H et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982; 66: 615-632.
8. Diehl V, Engert A, Re D. New strategies for the treatment of advanced-stage Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 897-914.
9. Eichenauer DA, Simhadri VL, von Strandmann EP et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res 2007; 67: 332-338.
10. Faivre-Chauvet A, Chatal JF. Radioimmunotherapy with yttrium-90 labelled ibritumomab-tiuxetan (Zevalin). EJHP Practice 2005: 4: 55-56.
11. Falini B, Flenghi L, Fedeli L et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30): immunohistological evidence. Br J Haematol 1992; 82: 38-45.
12. Fischer M, Grünwald F, Knapp WH et al. Leitlinie für die Radioimmuntherapie des CD20-positiven follikulären B-Zell-Non-Hodgkin- Lymphoms. Nuklearmedizin 2009; 48: 215-220.
13. Goldenberg DM. Targeted Therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713. (Pubitemid 34507123)
14. 90Y-labeled complementarity-determining-regiong-rafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies. Bioconjug Chem 1998; 9: 773-782.
15. 131I -labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114-123.
16. Hansen HP, Kisseleva T, Kobarg J et al. A zinc metallo proteinase is responsible for the release of CD30 on human tumor cell lines. Int J Cancer 1995; 63: 750-756.
17. Hansen HP, Recke A, Reineke U et al. Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cystine-rich domains 2 and 5. FASEB J 2004; 18: 893-895.
18. Hirsch B, Brauer J, Fischdick M et al. Anti-CD30 human IL-2 fusion proteins display strong and specific cytotoxicity in vivo. Curr Drug Targets 2009; 10: 110-117.
19. Hnatowich DJ. Label stability in serum of four radionuclides on DTPA-coupled antibodies-an evaluation. Int J Rad Appl Instrum B 1986; 13: 353-358.
20. Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998; 10: 457-470. (Pubitemid 28564375)
21. Horn-Lohrens O, Tiemann M, Lange H et al. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer 1995; 60: 539-544.
22. International Commission on Radiological Protection. Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP 1987; 18: 1-377.
23. 131I-tositumomab in clinical practice. J Nucl Med 2007; 48: 1767-1776.
24. Kasamon YL, Ambinder RF. Immunotherapies for Hodgkin's lymphoma. Crit Rev Oncol Hematol 2008; 66: 135-144.
25. Kiraly FJ, Kletting P, Reske S, Glatting G. Modellierung der Radioimmuntherapie mit anti-CD45-Antikörpern zur Verbesserung der Bio-distribution. Nuklearmedizin 2009; 48: 113-119.
26. Kobe C, Dietlein M, Mauz-Körholz C et al. FDG-PET beim Hodgkin-Lymphom. Nuklearmedizin 2008; 47: 235-238.
27. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J Nucl Med 2008; 49: 796-803.
28. Matthey B, Engert A, Barth S. Recombinant immuno toxins for the treatment of Hodgkin's disease. Int J Mol Med 2000; 6: 509-514.
29. Matthey B, Borchmann P, Schnell R et al. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. Int J Cancer 2004; 111: 568-574. (Pubitemid 39045324)
30. Meredith RF, Buchsbaum DJ. Pretargeted radioimmunotherapy. Int J Radiat Oncol Biol Phys 2006; 66 (2 Suppl): S57-59.
31. 90Y-labeled DOTA analogues conjugated to B72.3. Nucl Med Biol 2007; 34: 493-502.,
32. Paganelli G, Bartolomei M, Grana C. Radioimmuno therapy of brain tumor. Neurol Res 2006; 28: 518-522.
33. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009; 24: 155-161.
34. Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006; 66: 3351-3354
35. Scatchard O. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660-672.
36. Schnell R, Staak O, Borchmann P et al. A Phase I study with an anti-CD30 ricin A-chain immuno - toxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002; 8: 1779-1786. (Pubitemid 34633735)
37. Schnell R, Dietlein M, Staak JO et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 2005; 23: 4669-4678.
38. Schnell R, Dietlein M, Schomäcker K et al. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Onkologie 2008; 31: 49-51. (Pubitemid 351252941)
39. Schnitzer B. Hodgkin lymphoma. Hematol Oncol Clin North Am 2009; 23: 747-768.
40. Stein H, Gerdes J, Schwab U et al. Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer 1982; 30: 445-459. (Pubitemid 12003731)
41. Stein H, Schwarting R, Dallenbach F, Dienemann D. Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res 1989; 117: 14-26.
42. Tur MK, Neef I, Jäger G et al. Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy. Curr Pharm Des 2009; 15: 2693-2699.
43. Von Kalle C, Wolf J, Becker A et al. Growth of Hodgkin cell lines in severely combined immunodeficient mice. Int J Cancer. 1992; 52: 887-891.
44. Vriesendorp HM, Quadri SM, Wyllie CT et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999; 5: 3324-3329.
45. Wildes TM, Bartlett NL. Drug development for recurrent and refractory classical Hodgkin lymphoma. Leuk Lymphoma 2009; 50: 529-540.
46. Wong JY. Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66(2 Suppl): S8-S14.
47. 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 2006; 66: 8227-8232.